Take-home naloxone: research dispels concern that it increases drug-related risk behaviour

September 2023
Dr Samantha Colledge-Frisby examines the perception that people may engage in risk compensation when they have naloxone at hand.
Read more
June 2023

What are my tertiary alcohol and other drug qualification options?

The last scoping of tertiary level Australian alcohol and other drug (AOD) qualifications was undertaken two decades ago.
April 2023

Minimum unit pricing in the Northern Territory. What we know, and where to next

National Drug Research Institute
February 2023

Encounters with police drug detection dogs at music festivals among people who regularly use ecstasy and/or other illicit stimulants

Despite growing evidence challenging the effectiveness and legality of drug dog operations, and recommendations to cease operations at music festivals
November 2022

Facilitating First Nations Australians’ self-determination policy making processes

National Drug Research Institute
September 2022

Feasibility, consumer acceptability, and behavioural outcomes associated with take-home fentanyl test strips

July 2022

Opioid Agonist Therapy in Australia: A History

A new NCETA publication aims to document the substantial contribution that opioid agonist therapy (OAT) has made to public health and to the life of i
May 2022

Our systems undervalue prevention – FASD is a case in point

Australia spends less than 2% per annum of its health budget on prevention.
February 2022

Supporting peer workers and beyond: priorities for AOD workforce development

November 2021

No time to waste: Ageing, alcohol and pharmaceuticals

Co-authors: Ya Ping Lee, Fran Ackermann and Jun Chih, Curtin University, and Christopher Etherton-Beer, University of Western Australia
July 2021

Challenges and risks associated with the use of linked data and machine learning to address the opioid crisis

Co-authors: Professor Matthew Hickman, Dr Sebastiano Barbieri, and Professor Louisa Degenhardt

Pages